HIV-1 latency-reversing agents prostratin and bryostatin-1 induce blood-brain barrier disruption/inflammation and modulate leukocyte adhesion/transmigration

Journal of Immunology

Volumn 198, Issue 3, 2017, Pages 1229-1241

  Dental, Clélia ^a   Proust, Alizé ^a   Ouellet, Michel ^a   Barat, Corinne ^a   Tremblay, Michel J ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BRYOSTATIN 1; CD4 ANTIGEN; CD8 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; PROSTRATIN; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; AZACITIDINE; AZEPINE DERIVATIVE; BRYOSTATIN; CCL2 PROTEIN, HUMAN; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CYTOKINE; DECITABINE; F11R PROTEIN, HUMAN; HEXAMETHYLENEBISACETAMIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; PHORBOL ESTER; QUINAZOLINE DERIVATIVE;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL IMMORTALIZATION; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; MEMBRANE PERMEABILITY; MONOCYTE; MONOLAYER CULTURE; PROTEIN EXPRESSION; VIRUS LATENCY; ANALOGS AND DERIVATIVES; CELL ADHESION; CELL CULTURE; CELL MOTION; CHEMICALLY INDUCED; DRUG EFFECTS; INFLAMMATION; LEUKOCYTE; PHYSIOLOGY; SECRETION (PROCESS);

ACETAMIDES; AZACITIDINE; AZEPINES; BLOOD-BRAIN BARRIER; BRYOSTATINS; CELL ADHESION; CELL ADHESION MOLECULES; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CCL2; CYTOKINES; HIV-1; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES; PHORBOL ESTERS; QUINAZOLINES; RECEPTORS, CELL SURFACE; VIRUS LATENCY;

EID: 85014667238     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600742     Document Type: Article

References (65)

1. Mahajan, H. S., M. S. Mahajan, P. P. Nerkar, and A. Agrawal. 2014. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting. Drug Deliv. 21: 148-154.
2. Fiandra, L., M. Colombo, S. Mazzucchelli, M. Truffi, B. Santini, R. Allevi, M. Nebuloni, A. Capetti, G. Rizzardini, D. Prosperi, and F. Corsi. 2015. Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice. Nanomedicine (Lond.) 11: 1387-1397.
3. Kanmogne, G. D., S. Singh, U. Roy, X. Liu, J. McMillan, S. Gorantla, S. Balkundi, N. Smith, Y. Alnouti, N. Gautam, et al. 2012. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int. J. Nanomedicine 7: 2373-2388.
4. Dalpiaz, A., G. Paganetto, B. Pavan, M. Fogagnolo, A. Medici, S. Beggiato, and D. Perrone. 2012. Zidovudine and ursodeoxycholic acid conjugation: design of a new prodrug potentially able to bypass the active efflux transport systems of the central nervous system. Mol. Pharm. 9: 957-968.
5. Namanja, H. A., D. Emmert, D. A. Davis, C. Campos, D. S. Miller, C. A. Hrycyna, and J. Chmielewski. 2012. Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers. J. Am. Chem. Soc. 134: 2976-2980.
6. Hamer, D. H. 2004. Can HIV be cured? Mechanisms of HIV persistence and strategies to combat it. Curr. HIV Res. 2: 99-111.
7. Imai, K., H. Togami, and T. Okamoto. 2010. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J. Biol. Chem. 285: 16538-16545.
8. Bouchat, S., J. S. Gatot, K. Kabeya, C. Cardona, L. Colin, G. Herbein, S. De Wit, N. Clumeck, O. Lambotte, C. Rouzioux, et al. 2012. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS 26: 1473-1482.
9. Kauder, S. E., A. Bosque, A. Lindqvist, V. Planelles, and E. Verdin. 2009. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 5: e1000495.
10. Archin, N. M., K. S. Keedy, A. Espeseth, H. Dang, D. J. Hazuda, and D. M. Margolis. 2009. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 23: 1799-1806.
11. Contreras, X., M. Schweneker, C. S. Chen, J. M. McCune, S. G. Deeks, J. Martin, and B. M. Peterlin. 2009. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284: 6782-6789.
12. Contreras, X., M. Barboric, T. Lenasi, and B. M. Peterlin. 2007. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog. 3: 1459-1469.
13. Williams, S. A., L. F. Chen, H. Kwon, D. Fenard, D. Bisgrove, E. Verdin, and W. C. Greene. 2004. Prostratin antagonizes HIV latency by activating NFkappaB. J. Biol. Chem. 279: 42008-42017.
14. Mehla, R., S. Bivalkar-Mehla, R. Zhang, I. Handy, H. Albrecht, S. Giri, P. Nagarkatti, M. Nagarkatti, and A. Chauhan. 2010. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 5: e11160.
15. Darcis, G., A. Kula, S. Bouchat, K. Fujinaga, F. Corazza, A. Ait-Ammar, N. Delacourt, A. Melard, K. Kabeya, C. Vanhulle, et al. 2015. An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatin-1+JQ1 and ingenol-B+JQ1 to potently reactivate viral gene expression. PLoS Pathog. 11: e1005063.
16. Pérez, M., A. G. de Vinuesa, G. Sanchez-Duffhues, N. Marquez, M. L. Bellido, M. A. Muñoz-Fernandez, S. Moreno, T. P. Castor, M. A. Calzado, and E. Muñoz. 2010. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr. HIV Res. 8: 418-429.
17. Bouchat, S., N. Delacourt, A. Kula, G. Darcis, B. Van Driessche, F. Corazza, J. S. Gatot, A. Melard, C. Vanhulle, K. Kabeya, et al. 2015. Sequential treatment with 5-aza-2′-deoxycytidine and deacetylase inhibitors reactivates HIV-1. EMBO Mol. Med. 8: 117-138.
18. Martínez-Bonet, M., M. I. Clemente, M. J. Serramía, E. Muñoz, S. Moreno, and M.Á. Muñoz-Fernández. 2015. Synergistic activation of latent HIV-1 expression by novel histone deacetylase inhibitors and bryostatin-1. Sci. Rep. 5: 16445.
19. Reuse, S., M. Calao, K. Kabeya, A. Guiguen, J. S. Gatot, V. Quivy, C. Vanhulle, A. Lamine, D. Vaira, D. Demonte, et al. 2009. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 4: e6093.
20. Weksler, B., I. A. Romero, and P. O. Couraud. 2013. The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS 10: 16.
21. Poller, B., H. Gutmann, S. Krähenbühl, B. Weksler, I. Romero, P. O. Couraud, G. Tuffin, J. Drewe, and J. Huwyler. 2008. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J. Neurochem. 107: 1358-1368.
22. Weksler, B. B., E. A. Subileau, N. Perrière, P. Charneau, K. Holloway, M. Leveque, H. Tricoire-Leignel, A. Nicotra, S. Bourdoulous, P. Turowski, et al. 2005. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 19: 1872-1874.
23. Walsh, E., Y. Ueda, H. Nakanishi, and K. Yoshida. 1992. Neuronal survival and neurite extension supported by astrocytes co-cultured in transwells. Neurosci. Lett. 138: 103-106.
24. Gaillard, P. J., L. H. Voorwinden, J. L. Nielsen, A. Ivanov, R. Atsumi, H. Engman, C. Ringbom, A. G. de Boer, and D. D. Breimer. 2001. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur. J. Pharm. Sci. 12: 215-222.
25. Garcia, C. M., D. C. Darland, L. J. Massingham, and P. A. D'Amore. 2004. Endothelial cell-astrocyte interactions and TGF beta are required for induction of blood-neural barrier properties. Brain Res. Dev. Brain Res. 152: 25-38.
26. Luissint, A. C., C. Federici, F. Guillonneau, F. Chrétien, L. Camoin, F. Glacial, K. Ganeshamoorthy, and P. O. Couraud. 2012. Guanine nucleotide-binding protein Gαi2: a new partner of claudin-5 that regulates tight junction integrity in human brain endothelial cells. J. Cereb. Blood Flow Metab. 32: 860-873.
27. Sun, M., H. Fu, H. Cheng, Q. Cao, Y. Zhao, X. Mou, X. Zhang, X. Liu, and Y. Ke. 2012. A dynamic real-time method for monitoring epithelial barrier function in vitro. Anal. Biochem. 425: 96-103.
28. Kubicek, S., R. J. O'Sullivan, E. M. August, E. R. Hickey, Q. Zhang, M. L. Teodoro, S. Rea, K. Mechtler, J. A. Kowalski, C. A. Homon, et al. 2007. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 25: 473-481.
29. Chang, Y., X. Zhang, J. R. Horton, A. K. Upadhyay, A. Spannhoff, J. Liu, J. P. Snyder, M. T. Bedford, and X. Cheng. 2009. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat. Struct. Mol. Biol. 16: 312-317.
30. Tachibana, M., J. Ueda, M. Fukuda, N. Takeda, T. Ohta, H. Iwanari, T. Sakihama, T. Kodama, T. Hamakubo, and Y. Shinkai. 2005. Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. Genes Dev. 19: 815-826.
31. Marks, P. A. 2007. Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-1356.
32. Archin, N. M., A. Espeseth, D. Parker, M. Cheema, D. Hazuda, and D. M. Margolis. 2009. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25: 207-212.
33. Bartholomeeusen, K., K. Fujinaga, Y. Xiang, and B. M. Peterlin. 2013. Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J. Biol. Chem. 288: 14400-14407.
34. Fleegal, M. A., S. Hom, L. K. Borg, and T. P. Davis. 2005. Activation of PKC modulates blood-brain barrier endothelial cell permeability changes induced by hypoxia and posthypoxic reoxygenation. Am. J. Physiol. Heart Circ. Physiol. 289: H2012-H2019.
35. Kanmogne, G. D., K. Schall, J. Leibhart, B. Knipe, H. E. Gendelman, and Y. Persidsky. 2007. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J. Cereb. Blood Flow Metab. 27: 123-134.
36. Rigor, R. R., B. T. Hawkins, and D. S. Miller. 2010. Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain. J. Cereb. Blood Flow Metab. 30: 1373-1383.
37. Willis, C. L., D. S. Meske, and T. P. Davis. 2010. Protein kinase C activation modulates reversible increase in cortical blood-brain barrier permeability and tight junction protein expression during hypoxia and posthypoxic reoxygenation. J. Cereb. Blood Flow Metab. 30: 1847-1859.
38. Kim, Y. A., S. L. Park, M. Y. Kim, S. H. Lee, E. J. Baik, C. H. Moon, and Y. S. Jung. 2010. Role of PKCbetaII and PKCdelta in blood-brain barrier permeability during aglycemic hypoxia. Neurosci. Lett. 468: 254-258.
39. Korin, Y. D., D. G. Brooks, S. Brown, A. Korotzer, and J. A. Zack. 2002. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J. Virol. 76: 8118-8123.
40. Stamatovic, S. M., R. F. Keep, S. L. Kunkel, and A. V. Andjelkovic. 2003. Potential role of MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase. J. Cell Sci. 116: 4615-4628.
41. Yao, Y., and S. E. Tsirka. 2011. Truncation of monocyte chemoattractant protein 1 by plasmin promotes blood-brain barrier disruption. J. Cell Sci. 124: 1486-1495.
42. Song, L., and J. S. Pachter. 2004. Monocyte chemoattractant protein-1 alters expression of tight junction-associated proteins in brain microvascular endothelial cells. Microvasc. Res. 67: 78-89.
43. Keaney, J., and M. Campbell. 2015. The dynamic blood-brain barrier. FEBS J. 282: 4067-4079.
44. Gray, L. R., H. On, E. Roberts, H. K. Lu, M. A. Moso, J. A. Raison, C. Papaioannou, W. J. Cheng, A. M. Ellett, J. C. Jacobson, et al. 2016. Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells. J. Neurovirol. 22: 455-463.
45. Marks, P. A., V. M. Richon, and R. A. Rifkind. 2000. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92: 1210-1216.
46. Patel, K., J. Dickson, S. Din, K. Macleod, D. Jodrell, and B. Ramsahoye. 2010. Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res. 38: 4313-4324.
47. Schermelleh, L., F. Spada, H. P. Easwaran, K. Zolghadr, J. B. Margot, M. C. Cardoso, and H. Leonhardt. 2005. Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat. Methods 2: 751-756.
48. Waschke, J., N. Golenhofen, T. V. Kurzchalia, and D. Drenckhahn. 2006. Protein kinase C-mediated endothelial barrier regulation is caveolin-1-dependent. Histochem. Cell Biol. 126: 17-26.
49. Sonobe, Y., H. Takeuchi, K. Kataoka, H. Li, S. Jin, M. Mimuro, Y. Hashizume, Y. Sano, T. Kanda, T. Mizuno, and A. Suzumura. 2009. Interleukin-25 expressed by brain capillary endothelial cells maintains blood-brain barrier function in a protein kinase Cepsilon-dependent manner. [Published erratum appears in 2016 J. Biol. Chem. 291: 12573.] J. Biol. Chem. 284: 31834-31842.
50. Avison, M. J., A. Nath, R. Greene-Avison, F. A. Schmitt, R. N. Greenberg, and J. R. Berger. 2004. Neuroimaging correlates of HIV-associated BBB compromise. J. Neuroimmunol. 157: 140-146.
51. Tan, Z., R. C. Turner, R. L. Leon, X. Li, J. Hongpaisan, W. Zheng, A. F. Logsdon, Z. J. Naser, D. L. Alkon, C. L. Rosen, and J. D. Huber. 2013. Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke. Stroke 44: 3490-3497.
52. Hezareh, M., M. A. Moukil, I. Szanto, M. Pondarzewski, S. Mouche, N. Cherix, S. J. Brown, J. L. Carpentier, and M. Foti. 2004. Mechanisms of HIV receptor and co-receptor down-regulation by prostratin: role of conventional and novel PKC isoforms. Antivir. Chem. Chemother. 15: 207-222.
53. Yuan, L., L. Qiao, F. Wei, J. Yin, L. Liu, Y. Ji, D. Smith, N. Li, and D. Chen. 2013. Cytokines in CSF correlate with HIV-associated neurocognitive disorders in the post-HAART era in China. J. Neurovirol. 19: 144-149.
54. Mehla, R., S. Bivalkar-Mehla, M. Nagarkatti, and A. Chauhan. 2012. Programming of neurotoxic cofactor CXCL-10 in HIV-1-associated dementia: abrogation of CXCL-10-induced neuro-glial toxicity in vitro by PKC activator. J. Neuroinflammation 9: 239.
55. Hong, S., and W. A. Banks. 2015. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav. Immun. 45: 1-12.
56. Laverda, A. M., P. Gallo, A. De Rossi, S. Sivieri, P. Cogo, A. Pagliaro, L. Chieco-Bianchi, and B. Tavolato. 1994. Cerebrospinal fluid analysis in HIV-1-infected children: immunological and virological findings before and after AZT therapy. Acta Paediatr. 83: 1038-1042.
57. Eugenin, E. A., K. Osiecki, L. Lopez, H. Goldstein, T. M. Calderon, and J. W. Berman. 2006. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J. Neurosci. 26: 1098-1106.
58. Zhang, J., G. B. Sadowska, X. Chen, S. Y. Park, J. E. Kim, C. A. Bodge, E. Cummings, Y. P. Lim, O. Makeyev, W. G. Besio, et al. 2015. Anti-IL-6 neutralizing antibody modulates blood-brain barrier function in the ovine fetus. FASEB J. 29: 1739-1753.
59. Desai, T. R., N. J. Leeper, K. L. Hynes, and B. L. Gewertz. 2002. Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J. Surg. Res. 104: 118-123.
60. Rochfort, K. D., L. E. Collins, A. McLoughlin, and P. M. Cummins. 2016. Tumour necrosis factor-α-mediated disruption of cerebrovascular endothelial barrier integrity in vitro involves the production of proinflammatory interleukin-6. J. Neurochem. 136: 564-572.
61. Abadier, M., N. Haghayegh Jahromi, L. Cardoso Alves, R. Boscacci, D. Vestweber, S. Barnum, U. Deutsch, B. Engelhardt, and R. Lyck. 2015. Cell surface levels of endothelial ICAM-1 influence the transcellular or paracellular T-cell diapedesis across the blood-brain barrier. Eur. J. Immunol. 45: 1043-1058.
62. Gorina, R., R. Lyck, D. Vestweber, and B. Engelhardt. 2014. β2 integrinmediated crawling on endothelial ICAM-1 and ICAM-2 is a prerequisite for transcellular neutrophil diapedesis across the inflamed blood-brain barrier. J. Immunol. 192: 324-337.
63. Díaz, L., M. Martínez-Bonet, J. Sánchez, A. Fernández-Pineda, J. L. Jiménez, E. Muñoz, S. Moreno, S. Álvarez, and M. A. Muñoz-Fernández. 2015. Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-κBdependent mechanism. Sci. Rep. 5: 12442.
64. Martínez-Bonet, M., M. I. Clemente, S. Álvarez, L. Díaz, D. García-Alonso, E. Muñoz, S. Moreno, and M. A. Muñoz-Fernández. 2015. Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal. Antiviral Res. 123: 163-171.
65. Gutiérrez, C., S. Serrano-Villar, N. Madrid-Elena, M. J. Perez-Elias, M. E. Martín, C. Barbas, J. Ruipérez, E. Muñoz, M. A. Muñoz-Fernandez, T. Castor, and S. Moreno. 2016. Bryostatin-1 for latent virus reactivation in HIVinfected patients on antiretroviral therapy. AIDS 30: 1385-1392.